Treatment of invasive fungal diseases in cancer patients—Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Open Access
- 31 March 2020
- Vol. 63 (7), 653-682
- https://doi.org/10.1111/myc.13082
Abstract
Background Invasive fungal diseases remain a major cause of morbidity and mortality in cancer patients undergoing intensive cytotoxic therapy. The choice of the most appropriate antifungal treatment (AFT) depends on the fungal species suspected or identified, the patient’s risk factors (e.g. length and depth of granulocytopenia) and the expected side effects. Objectives Since the last edition of recommendations for “Treatment of invasive fungal infections in cancer patients” of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) in 2013, treatment strategies were gradually moving away from solely empirical therapy of presumed or possible invasive fungal diseases (IFD) towards pre‐emptive therapy of probable IFD. Methods The guideline was prepared by German clinical experts for infections in cancer patients in a stepwise consensus process. Medline was systematically searched for English language publications from January 1975 up to September 2019 using the key terms such as “invasive fungal infection” and/or “invasive fungal disease” and at least one of the following: antifungal agents, cancer, hematological malignancy, antifungal therapy, neutropenia, granulocytopenia, mycoses, aspergillosis, candidosis, mucormycosis. Results AFT of IFDs in cancer patients may include not only antifungal agents but also non‐pharmacologic treatment. In addition, the armamentarium of antifungals for treatment of IFDs has been broadened (e.g. licensing of isavuconazole). Additional antifungals are currently under investigation or in clinical trials. Conclusions Here, updated recommendations for the treatment of proven or probable IFDs are given. All recommendations including the levels of evidence are summarized in tables to give the reader rapid access to key information.Keywords
This publication has 317 references indexed in Scilit:
- The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trialJournal of Antimicrobial Chemotherapy, 2011
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEuropean Journal of Cancer, 2011
- Clinical importance of the CYP2C19*17 variant allele for voriconazoleBritish Journal of Clinical Pharmacology, 2010
- Factors Associated with Mortality in Transplant Patients with Invasive AspergillosisClinical Infectious Diseases, 2010
- Combination Flucytosine and High‐Dose Fluconazole Compared with Fluconazole Monotherapy for the Treatment of Cryptococcal Meningitis: A Randomized Trial in MalawiClinical Infectious Diseases, 2010
- Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2010
- Lipid Formulations of Amphotericin B Significantly Improve Outcome in Solid Organ Transplant Recipients with Central Nervous System CryptococcosisClinical Infectious Diseases, 2009
- Granulocyte transfusion therapy: a new era?Current Opinion in Hematology, 2009
- Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus CriteriaClinical Infectious Diseases, 2008
- Combination Polyene‐Caspofungin Treatment of Rhino‐Orbital‐Cerebral MucormycosisClinical Infectious Diseases, 2008